Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.

Mohammed F, Stones DH, Zarling AL, Willcox CR, Shabanowitz J, Cummings KL, Hunt DF, Cobbold M, Engelhard VH, Willcox BE.

Oncotarget. 2017 Apr 8;8(33):54160-54172. doi: 10.18632/oncotarget.16952. eCollection 2017 Aug 15.

2.

Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma.

Malaker SA, Ferracane MJ, Depontieu FR, Zarling AL, Shabanowitz J, Bai DL, Topalian SL, Engelhard VH, Hunt DF.

J Proteome Res. 2017 Jan 6;16(1):228-237. doi: 10.1021/acs.jproteome.6b00496. Epub 2016 Sep 13.

3.

MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.

Zarling AL, Obeng RC, Desch AN, Pinczewski J, Cummings KL, Deacon DH, Conaway M, Slingluff CL Jr, Engelhard VH.

Cancer Res. 2014 Dec 1;74(23):6784-95. doi: 10.1158/0008-5472.CAN-14-0043. Epub 2014 Oct 8.

4.

Internalizing and externalizing symptoms in young children exposed to intimate partner violence: examining intervening processes.

Zarling AL, Taber-Thomas S, Murray A, Knuston JF, Lawrence E, Valles NL, DeGarmo DS, Bank L.

J Fam Psychol. 2013 Dec;27(6):945-55. doi: 10.1037/a0034804.

5.

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.

Cobbold M, De La Peña H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, Abelin JG, Malaker SA, Zarling AL, Huang HW, Goodyear O, Freeman SD, Shabanowitz J, Pratt G, Craddock C, Williams ME, Hunt DF, Engelhard VH.

Sci Transl Med. 2013 Sep 18;5(203):203ra125. doi: 10.1126/scitranslmed.3006061.

6.

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.

Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, English AM, Shabanowitz J, Engelhard VH, Hunt DF, Topalian SL.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12073-8. doi: 10.1073/pnas.0903852106. Epub 2009 Jul 6.

7.

Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.

Mohammed F, Cobbold M, Zarling AL, Salim M, Barrett-Wilt GA, Shabanowitz J, Hunt DF, Engelhard VH, Willcox BE.

Nat Immunol. 2008 Nov;9(11):1236-43. doi: 10.1038/ni.1660. Epub 2008 Oct 5.

8.

Strategies and challenges in eliciting immunity to melanoma.

Ferguson AR, Nichols LA, Zarling AL, Thompson ED, Brinkman CC, Hargadon KM, Bullock TN, Engelhard VH.

Immunol Rev. 2008 Apr;222:28-42. doi: 10.1111/j.1600-065X.2008.00620.x.

9.

Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.

Zarling AL, Polefrone JM, Evans AM, Mikesh LM, Shabanowitz J, Lewis ST, Engelhard VH, Hunt DF.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14889-94. Epub 2006 Sep 25.

10.

Post-translational modifications of naturally processed MHC-binding epitopes.

Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL.

Curr Opin Immunol. 2006 Feb;18(1):92-7. Epub 2005 Dec 15. Review.

PMID:
16343885
11.

Tapasin is a facilitator, not an editor, of class I MHC peptide binding.

Zarling AL, Luckey CJ, Marto JA, White FM, Brame CJ, Evans AM, Lehner PJ, Cresswell P, Shabanowitz J, Hunt DF, Engelhard VH.

J Immunol. 2003 Nov 15;171(10):5287-95.

12.

Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire.

Engelhard VH, Brickner AG, Zarling AL.

Mol Immunol. 2002 Oct;39(3-4):127-37. Review.

PMID:
12200045
13.

The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing.

Brickner AG, Warren EH, Caldwell JA, Akatsuka Y, Golovina TN, Zarling AL, Shabanowitz J, Eisenlohr LC, Hunt DF, Engelhard VH, Riddell SR.

J Exp Med. 2001 Jan 15;193(2):195-206.

14.

Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo.

Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH.

J Exp Med. 2000 Dec 18;192(12):1755-62.

15.

Induction of primary human CD8+ T lymphocyte responses in vitro using dendritic cells.

Zarling AL, Johnson JG, Hoffman RW, Lee DR.

J Immunol. 1999 May 1;162(9):5197-204.

16.
17.

Correction of the HLA-Cw3 genomic sequence tentatively identifies it as HLA-Cw*0304.

Zarling AL, Smith KD, Lutz CT, Lee DR.

Immunogenetics. 1996;44(1):82-3. No abstract available.

PMID:
8613148

Supplemental Content

Loading ...
Support Center